TRIM63 antibody is a research tool targeting TRIM63 (Tripartite Motif-Containing Protein 63), also known as Muscle RING-finger protein-1 (MuRF1). TRIM63 is a member of the TRIM protein family, characterized by RING, B-box, and coiled-coil domains, which mediate ubiquitination and protein degradation via the ubiquitin-proteasome system. Primarily expressed in skeletal and cardiac muscle, TRIM63 functions as an E3 ubiquitin ligase, regulating muscle atrophy by tagging structural proteins like titin and troponin for proteasomal breakdown. Its expression is upregulated during conditions inducing muscle wasting, including cancer cachexia, sepsis, diabetes, and disuse atrophy, making it a key biomarker for studying muscle degradation pathways.
TRIM63 antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to detect TRIM63 expression levels in tissues or cell cultures. These antibodies aid in exploring molecular mechanisms underlying muscle atrophy, evaluating therapeutic interventions, and understanding TRIM63's role in cellular stress responses. Additionally, they support research into cardiac hypertrophy and heart failure, where TRIM63 modulates sarcomeric protein turnover. As TRIM63 is a potential therapeutic target for muscle-wasting disorders, its antibodies are crucial for validating drug efficacy and elucidating signaling pathways, such as the AKT-FOXO axis, that regulate its activity. Their specificity and reliability make TRIM63 antibodies essential in both basic and translational muscle biology research.